Free Trial
NYSE:BVS

Bioventus 3/12/2024 Earnings Report

Bioventus logo
$6.51 -0.05 (-0.76%)
As of 01:03 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Bioventus EPS Results

Actual EPS
$0.07
Consensus EPS
$0.06
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Bioventus Revenue Results

Actual Revenue
$135.42 million
Expected Revenue
$124.84 million
Beat/Miss
Beat by +$10.58 million
YoY Revenue Growth
N/A

Bioventus Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Conference Call Audio

Earnings Conference Call
Bioventus
00:00 / 00:00

Bioventus Earnings Headlines

Analyzing Bioventus (NYSE:BVS) and Teleflex (NYSE:TFX)
Contrasting Bioventus (NYSE:BVS) & RenovaCare (OTCMKTS:RCAR)
Elon Reveals Why There Soon Won’t Be Any Money For Social Security
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
Bioventus: Q1 Earnings Snapshot
See More Bioventus Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bioventus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bioventus and other key companies, straight to your email.

About Bioventus

Bioventus (NYSE:BVS), a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

View Bioventus Profile

More Earnings Resources from MarketBeat